ESOTRAC - listening to light


listening to light

ESOTRAC - addressing an urgent medical need


addressing an urgent medical need

ESOTRAC - challenging endeavor


challenging endeavor

ESOTRAC - increasing penetration depth & adaptation of software


increasing penetration depth & adaptation of software

ESOTRAC - offering multispectral analysis


offering multispectral analysis

ESOTRAC - international interdisciplinary team


international interdisciplinary team




ESOTRAC, a 4-year research program bringing together engineers and physicians, aims to significantly improve the detection of early-stage esophageal cancer. The interdisciplinary, 5-country research team will develop an innovative endoscope that combines sensing of pathophysiological tissue signatures resolved by multi-spectral optoacoustic (photoacoustic) tomography (MSOT) with morphological disease signatures provided by optical coherence tomography (OCT).




More than 450.000 people are diagnosed with esophageal cancer (EC) each year worldwide and ~400.000 die annually from the disease. The high mortality rate is attributed to the late detection of the disease, largely due to insufficient detection methods today. Besides loss of life, treating late disease incurs costs in the range of $80,000-250,000 per patient lifetime making esophageal cancer among the most expensive diseases to treat in oncology today. Risk factors, including obesity, chronic gastroesophageal reflux disease (GERD) and Barret’s esophagus, implicate diagnostically a much larger population. It is estimated that at least 100 million people suffer of GERD in Western Countries and that ~10 million people in Western countries live with Barrett’s esophagus. Alarmingly, due to an aging and more overweight population the incidence rates of GERD, Barrett’s esophagus and EC are increasing.

Today, EC detection and diagnosis is typically based on white-light endoscopy (WLE), i.e. the visual inspection of the esophagus lumen through an optical system (endoscope) and subsequent pathological analysis of biopsied samples. Human vision however is insensitive to detecting early disease (dysplasia / sub-surface lesions) and lacks specificity and staging ability compromising disease prognosis. Due to WLE limitations, random biopsies may be prescribed to improve the chances of detecting early disease and tumor staging. Random tissue sampling is nevertheless sub-optimal and it may miss EC. Therefore, EC is often detected late in the course of development, which decreases the five year survival rate by more than 80% compared to early detection of the disease.

Thus, a novel tool for early detection of EC is urgently needed.



Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt
University of Cambridge
Medizinische Universität Wien
RayFos Ltd.
Ascenion GmbH
Amplitude Systèmes
Danmarks Tekniske Universitet


Halftime in ESOTRAC: 4th consortium meeting in Vienna

The 4th consortium meeting of ESOTRAC took place from January 10-11, 2019 at Hotel & Palais Strudlhof in Vienna, hosted by the Medical University of...


3rd consortium meeting in Kopenhagen

The Technical University of Denmark hosted the 3rd consortium meeting from July 2-3, 2018 @ the Park Inn by Radisson in Kopenhagen.  Joined by one of...

EMIM conference in San Sebastian, Spain


ESOTRAC invited for a special session at the recent EMIM conference in San Sebastian, Spain

ESOTRAC researchers hosted a well-attended special session on “Early detection of esophageal cancer with advances in photonic imaging” on March 22nd...


The first consortium meeting

The ESOTRAC consortium gathered for their first consortium meeting at Hotel Europa, Munich from July 20-21, 2017. All partners reported on the...


Start of the ESOTRAC website

The website of the ESOTRAC project was started on 28th of April, 2017.

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.